Direct Angiotensin II Type 2 Receptor Stimulation Ameliorates Insulin Resistance in Type 2 Diabetes Mice with PPARγ Activation

Kousei Ohshima(Boston University), Masatsugu Horiuchi(Ehime University), Jun Iwanami(Ehime University), Kana Tsukuda(Ehime University), U. Muscha Steckelings(University of Southern Denmark), Björn Dahlöf(Sahlgrenska University Hospital), Fei Jing(Baoji University of Arts and Sciences), Tomas Unger(Maastricht University), Akiyoshi Ogimoto(Ehime University), Jitsuo Higaki(Saiseikai Matsuyama Hospital), Li‐Juan Min(Ehime University), Masaki Mogi(Ehime University)

PLoS ONE

November 14, 2012

10.1371/journal.pone.0048387

Cited by 71

Related Papers

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

|The Lancet|2002|5.4k

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

|The Lancet|2003|3.8k

Erratum: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)

|Hypertension Research|2014|1.4k

In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction

|Nature Medicine|1997|589

Erratum: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)—Chapter 2

|Hypertension Research|2009|485